Puo-Hsien Le1,2, Kung-Hao Liang1,3, Ming-Ling Chang1,2, Chao-Wei Hsu1,2, Yi-Cheng Chen1,2, Chih-Lang Lin1,2, Wey-Ran Lin1,2, Ming-Wei Lai1,2, Chau-Ting Yeh4,2,3. 1. Liver Research Center, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan, R.O.C. 2. Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan, R.O.C. 3. Molecular Medicine Research Center, Chang Gung University, Taoyuan, Taiwan, R.O.C. 4. Liver Research Center, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan, R.O.C. chautingy@gmail.com.
Abstract
BACKGROUND: A lower neutrophil-to-lymphocyte ratio (NLR) was found to be associated with better clinical outcomes in hepatitis B-related liver cirrhosis and hepatocellular carcinoma. We aimed to identify pre-therapeutic variables capable of predicting NLR changes in patients with hepatitis B receiving peginterferon therapy. PATIENTS AND METHODS: The baseline clinicopathological data were analyzed to correlate with NLR changes before and 1 year after peginterferon treatment in 71 patients with hepatitis B. RESULTS: Univariate analysis revealed that pre-treatment NLR itself negatively predicted NLR changes following peginterferon treatment (odds ratio(OR)=0.320, p=0.013). Further analysis identified pre-treatment NLR, hemoglobin and hepatitis B surface antigen level as independent predictors for NLR changes (adjusted p=0.028, 0.005, and 0.028, respectively). A predictive score composed of these three factors had an area under the curve of 76.5% (p<0.001). CONCLUSION: Pretreatment NLR, hemoglobin and hepatitis B surface antigen level in combination, effectively predicted NLR changes following peginterferon treatment. Copyright
BACKGROUND: A lower neutrophil-to-lymphocyte ratio (NLR) was found to be associated with better clinical outcomes in hepatitis B-related liver cirrhosis and hepatocellular carcinoma. We aimed to identify pre-therapeutic variables capable of predicting NLR changes in patients with hepatitis B receiving peginterferon therapy. PATIENTS AND METHODS: The baseline clinicopathological data were analyzed to correlate with NLR changes before and 1 year after peginterferon treatment in 71 patients with hepatitis B. RESULTS: Univariate analysis revealed that pre-treatment NLR itself negatively predicted NLR changes following peginterferon treatment (odds ratio(OR)=0.320, p=0.013). Further analysis identified pre-treatment NLR, hemoglobin and hepatitis B surface antigen level as independent predictors for NLR changes (adjusted p=0.028, 0.005, and 0.028, respectively). A predictive score composed of these three factors had an area under the curve of 76.5% (p<0.001). CONCLUSION: Pretreatment NLR, hemoglobin and hepatitis B surface antigen level in combination, effectively predicted NLR changes following peginterferon treatment. Copyright
Authors: K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween Journal: J Hepatol Date: 1995-06 Impact factor: 25.083
Authors: Henry Lik-Yuen Chan; Alex Thompson; Michelle Martinot-Peignoux; Teerha Piratvisuth; Markus Cornberg; Maurizia Rossana Brunetto; Hans L Tillmann; Jia-Horng Kao; Ji-Dong Jia; Heiner Wedemeyer; Stephen Locarnini; Harry L A Janssen; Patrick Marcellin Journal: J Hepatol Date: 2011-06-28 Impact factor: 25.083
Authors: H Tsukuma; T Hiyama; S Tanaka; M Nakao; T Yabuuchi; T Kitamura; K Nakanishi; I Fujimoto; A Inoue; H Yamazaki Journal: N Engl J Med Date: 1993-06-24 Impact factor: 91.245
Authors: M Espinosa; M D Arenas; M D Aumente; G Barril; J M Buades; B Aviles; D Carretero; M A Alvarez-Lara; F Carnicer; A Martin-Malo; P Aljama Journal: Clin Nephrol Date: 2007-06 Impact factor: 0.975
Authors: Aaron Potretzke; Luke Hillman; Kelvin Wong; Fangfang Shi; Ryan Brower; Stephanie Mai; Jeremy P Cetnar; Edwin Jason Abel; Tracy M Downs Journal: Urol Oncol Date: 2014-03-12 Impact factor: 3.498